Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492942 · ClinicalTrials.gov registry record · NA
Records for Alcohol Care Enhancement
A NA study, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 134
- Enrollment target
NCT05492942: Completed NA study, sponsored by Boston Medical Center.
NCT05492942 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 134 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05492942, a NA study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 134 participants
- Enrollment target
Study Summary
Unhealthy alcohol use (the spectrum from risky consumption through alcohol use disorder, AUD) is a leading cause of preventable death in the US (88,424 deaths annually costing $249 billion a year), and alcohol-related health harms (e.g. AUD itself, cirrhosis) are increasing. Despite high frequency of contacts with the medical system, most people with unhealthy alcohol use do not receive evidence-based interventions due to factors such as stigma, lack of knowledge, challenges with implementing and maintaining tool-based screening, time or prioritization constraints, and more. Electronic health records (EHRs), Best Practice Advisories (BPA) and registries are known and practical tools to improve management and care of chronic disease by aggregating information about the target population, and by assisting the clinician in reminders, decision support, and disease-specific care management. EHRs may help clinicians identify, assess, treat and monitor care when assisted by targeted staff support such as a clinical care manager (CCM) and population health manager (PHM). These support staff help to track outcomes of care and treatments, allowing for increased engagement with the population, and facilitation of care.
Primary Outcome
The percent of new AUD diagnosis episodes that meet criteria for AUD treatment engagement among patients with a new AUD diagnosis on a randomized clinician's panel. Engagement is defined as having two or more healthcare services (inclusive of AUD medication) with a diagnosis of AUD within 34 days of meeting initiation, which is defined as having a healthcare service for AUD within 14 days of a new AUD diagnosis. A new AUD diagnosis is defined as a health service in which a patient receives a new
Interventions
- BEHAVIORAL Best Practice Advisory (BPA) and Population Health Management (PHM)
- BEHAVIORAL Best Practice Advisory (BPA) and Clinical Care Management (CCM)
- BEHAVIORAL Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2024-11-28 |
| Phase | NA |
What the finished NCT05492942 record still lists
NCT05492942 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 3 interventions - of which Best Practice Advisory (BPA) and Population Health Management (PHM) is the first listed.
NCT05492942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05492942 about?
NCT05492942 is a clinical study titled "Records for Alcohol Care Enhancement". Unhealthy alcohol use (the spectrum from risky consumption through alcohol use disorder, AUD) is a leading cause of preventable death in the US (88,424 deaths annually costing $249 billion a year), and alcohol-related health harms (e.g. AUD itself, cirrhosis) are increasing. Despite high frequency o...
What is the current status of trial NCT05492942?
This trial is currently completed. It is a NA study. The enrollment target is 134 participants. The study started on 2022-11-11. Estimated completion is 2024-11-28.
What interventions are being tested in trial NCT05492942?
The interventions under investigation include: Best Practice Advisory (BPA) and Population Health Management (PHM) (BEHAVIORAL), Best Practice Advisory (BPA) and Clinical Care Management (CCM) (BEHAVIORAL), Best Practice Advisory (BPA) and Population Health Management (PHM) and Clinical Care Management (CCM) (BEHAVIORAL).
Who is sponsoring clinical trial NCT05492942?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05492942's enrollment target sits among peer trials
134 728th of 2000 higher than 1,272 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI